{"title":"Flector","description":"\u003cp\u003eCerotti medicati Flector a base di diclofenac e di piroxicam, da applicare sulla zona dolente per il trattamento locale di stati dolorosi e infiammatori di articolazioni, muscoli, tendini e legamenti. Disponibili nella versione classica e nella Unidie a una sola applicazione al giorno. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"flector-180mg-5-cerotti-medicati","title":"Flector 180mg 5 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: • active ingredient: diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium diclofenac); • excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, perfume in turn containing amyl cinnamal, amyl cinnamal alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, polyvinylpyrrolidone, sorbitol solution 70%, kaolin, titanium dioxide, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, disodium edetate, tartaric acid, dihydroxyaluminium aminoacetate, sodium carboxymethylcellulose, sodium polyacrylate, 1-3-butylene glycol, polysorbate 80, perfume, purified water, synthetic felt, plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e: The medicine should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e: The usual dosage regimen is 1 or 2 patches per day (one application every 12 or 24 hours) for a period of up to 14 days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003ci\u003ePediatric population\u003c\/i\u003e. \u003ci\u003eChildren and adolescents under 16 years of age\u003c\/i\u003e: the use of this medicated plaster is not recommended because insufficient data are available to evaluate the safety and efficacy of the medicine (see section 4.3). \u003ci\u003eIn adolescents aged 16 years and older\u003c\/i\u003e: If the medicine is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, a re-evaluation is necessary. Advise the patient or the adolescent's relatives to consult the doctor. \u003ci\u003eElderly\u003c\/i\u003e: This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e: For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e: Cut the bag containing the medicated plaster as indicated. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band (the package contains a tubular net). Close the envelope carefully. The patch must be used entirely. Avoid contact with eyes or mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131188150599,"sku":"027757032","price":15.72,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-5-cerotti-medicati-farmacia-dottor-tili-1213792401.jpg?v=1767132569"},{"product_id":"flector-180mg-10-cerotti-medicati","title":"Flector 180mg 10 medicated plasters","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLocal treatment of painful and inflammatory states of a rheumatic or traumatic nature of: • Joints; • Muscles; • Tendons; • Ligaments.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eA 180 mg medicated plaster contains: • active ingredient: diclofenac hydroxyethylpyrrolidine 180 mg (equal to 140 mg of sodium diclofenac); • excipients with known effects: propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, perfume in turn containing amyl cinnamal, amyl cinnamal alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate. For the complete list of excipients see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGelatin, polyvinylpyrrolidone, sorbitol solution 70%, kaolin, titanium dioxide, propylene glycol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, disodium edetate, tartaric acid, dihydroxyaluminium aminoacetate, sodium carboxymethylcellulose, sodium polyacrylate, 1-3-butylene glycol, polysorbate 80, perfume, purified water, synthetic felt, plastic film.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to acetylsalicylic acid or to other analgesics or other non-steroidal anti-inflammatory preparations (NSAIDs) or to any of the excipients listed in paragraph 6.1. • Patients in whom asthma attacks, urticaria or acute rhinitis have occurred after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). • Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns, or wounds. • Third trimester of pregnancy (see section 4.6). • Patients with active peptic ulcer. \u003ci\u003e \u003cu\u003eChildren and adolescents\u003c\/u\u003e \u003c\/i\u003e: Use in children and adolescents under 16 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. \u003cu\u003eDosage\u003c\/u\u003e: The medicine should only be applied to intact, healthy skin and should not be applied when bathing or showering. The diclofenac medicated plaster must be used for the shortest time possible in relation to the indication of use. \u003ci\u003eAdults\u003c\/i\u003e: The usual dosage regimen is 1 or 2 patches per day (one application every 12 or 24 hours) for a period of up to 14 days. Advise the patient to consult their doctor if they do not experience improvement following the recommended treatment period (see section 4.4). \u003ci\u003ePediatric population\u003c\/i\u003e. \u003ci\u003eChildren and adolescents under 16 years of age\u003c\/i\u003e: the use of this medicated plaster is not recommended because insufficient data are available to evaluate the safety and efficacy of the medicine (see section 4.3). \u003ci\u003eIn adolescents aged 16 years and older\u003c\/i\u003e: If the medicine is needed for a treatment period longer than 7 days for pain relief or if symptoms worsen, a re-evaluation is necessary. Advise the patient or the adolescent's relatives to consult the doctor. \u003ci\u003eElderly\u003c\/i\u003e: This medicine should be used with caution in elderly patients as they are more predisposed to side effects (see section 4.4). \u003ci\u003ePatients with hepatic or renal insufficiency\u003c\/i\u003e: For the use of diclofenac medicated plasters in patients with hepatic or renal insufficiency, consult section 4.4. \u003cu\u003eMethod of administration\u003c\/u\u003e: Cut the bag containing the medicated plaster as indicated. Take out a medicated plaster, remove the plastic film used to protect the adhesive surface and apply the plaster to the joint or painful surface. If necessary, the patch can be held in place using an elastic band (the package contains a tubular net). Close the envelope carefully. The patch must be used entirely. Avoid contact with eyes or mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIf diclofenac medicated plasters are used on large skin surfaces and for a prolonged period of time, the possibility of systemic adverse events cannot be excluded (see the Summary of Product Characteristics of the systemic formulations of diclofenac). The medicated plaster must be applied only to intact and healthy skin and must not be applied to damaged skin or open wounds. The patches should not come into contact with the eyes or mucous membranes. Asthmatic patients with chronic obstructive diseases of the bronchi, allergic rhinitis or inflammation of the nasal mucosa (nasal polyp) react with asthma attacks, local inflammation of the skin or mucosa (Quincke's edema) or urticaria to treatment with NSAIDs more often than other patients. The use, especially if prolonged, of this as well as other products for topical use can give rise to sensitization phenomena. In this case it is necessary to interrupt treatment and institute appropriate therapy. Although systemic absorption is minimal, the use of FLECTOR, as with any drug that inhibits prostaglandin synthesis and cyclooxygenase, is not recommended in women intending to become pregnant. The administration of FLECTOR should be suspended in women who have fertility problems or who are undergoing fertility investigations. Side effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. • Do not use with an occlusive dressing that does not allow air to pass through. • Treatment should be stopped immediately if a skin rash develops after applying the medicated plaster. • Do not simultaneously administer topically or systemically another medicinal product containing diclofenac or other NSAIDs. • Although systemic effects should be low, the medicated plaster should be used with caution in patients with renal, cardiac or hepatic impairment, history of peptic ulcer or inflammatory bowel disease or bleeding diathesis. Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more predisposed to side effects. • Patients should be advised not to expose themselves to direct sunlight or sun lamps for approximately one day after removal of the medicated plaster to reduce the risk of photosensitivity. \u003cu\u003eImportant information about some excipients\u003c\/u\u003e. FLECTOR contains: - methyl parahydroxybenzoate, propyl parahydroxybenzoate: may cause allergic reactions (even delayed); - 420 mg of propylene glycol in each patch: may cause skin irritation; - an aroma (perfume) in turn containing amyl cinnamal, amyl cinnamyl alcohol, benzyl alcohol, benzyl benzoate, benzyl salicylate, cinnammal, cinnamyl alcohol, citronellol, d-Limonene, eugenol, farinasol, geraniol, hexyl cinnamic aldehyde, hydroxycitronellal, isoeugenol, linalool, methyl heptin carbonate: may cause reactions allergic\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac following the use of medicated plasters is very low, the risk of developing clinically significant interactions with other medicinal products is negligible. Clinical investigations carried out with FLECTOR medicated plaster used in conjunction with other steroidal and non-steroidal anti-inflammatory drugs (salazopyrin, hydroxyquinoline, etc.) have not highlighted any interaction phenomena. However, the possibility of competition between the absorbed diclofenac and other drugs with high binding to plasma proteins cannot be excluded. Concomitant topical or systemic use of other drugs containing diclofenac or other NSAIDs is not recommended (see section 4.8).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are listed by frequency, most frequent first, using the following convention: common (≥ 1\/100, \u003c 1\/10); uncommon (≥ 1\/1,000, \u003c 1\/100); rare (≥ 1\/10,000, \u003c 1\/1,000); very rare (\u003c 1\/10,000); not known: cannot be estimated from available data. \u003cb\u003eTable 1 \u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Rash with pustules.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema, anaphylactoid reaction.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (including allergic dermatitis and contact dermatitis), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis (e.g. bullous erythema), dry skin.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity reactions\u003c\/p\u003e\n\u003cp\u003eSystemic pathologies and conditions relating to the administration site.\u003c\/p\u003e\n\u003cp\u003eCommon: Administration site reactions.\u003c\/p\u003e\n\u003cp\u003eFollowing applications for long periods of time on large skin surfaces, due to the amount of active ingredient that is absorbed, the appearance of systemic undesirable effects, especially at the gastrointestinal level, cannot be excluded. The use of the product in association with other drugs containing diclofenac can give rise to phenomena of hypersensitivity to light, skin rash with the formation of vesicles, eczema, erythema and, in rare cases, severe skin reactions (severe Stevens-Johnson, Lyell syndrome) (see section 4.5). \u003cu\u003eReporting of suspected adverse reactions.\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo cases of overdose have been reported with diclofenac medicated plasters. Should systemic side effects occur due to incorrect use or accidental overdose (e.g. in children) with the product, the general supportive measures to be taken in case of intoxication with non-steroidal anti-inflammatory drugs are recommended.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy\u003c\/b\u003e: The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Referring to the experience of treatment with NSAIDs for systemic administration, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy diclofenac should not be administered unless strictly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, at the end of pregnancy, to: - possible prolongation of bleeding time and anti-aggregating effect which can occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e: Like other NSAIDs, diclofenac passes into breast milk in small quantities. However, at therapeutic doses of diclofenac medicated plasters, no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, diclofenac medicated plasters should not be applied to the breasts of breastfeeding mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe application of diclofenac medicated plasters does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51131235336519,"sku":"027757044","price":22.23,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flector-180mg-10-cerotti-medicati-farmacia-dottor-tili-1213792316.jpg?v=1767143369"},{"product_id":"flectorartro-1-100-g-gel-in-contenitore-pressurizzato","title":"FlectorArtro 1% 100g gel in pressurized container","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSymptomatic local relief of pain and inflammatory states caused by post-traumatic injuries, such as contusions, sprains and tendinitis.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e100 g of gel contains 1 g of diclofenac sodium in the form of diclofenac epolamine. Excipients with known effects: propylene glycol, methyl benzoate. For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSoy Lecithin, Macrogolglycerol Hydroxystearate, Macrogol Stearate, Carbomer, Sodium Hydroxide, Isopropyl Alcohol, Fragrance (Floral PH–Y containing Benzyl Acetate, Phenylethyl Alcohol, Hydroxycitronellal, Paraguayan Petitgrain Oil, Cinnamic Alcohol, Propylene Glycol and Methyl Benzoate), Purified Water. Compressed air (for pressure vessel only)\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicine is contraindicated in the following cases: – Hypersensitivity to diclofenac, acetylsalicylic acid (aspirin) or other NSAIDs. – Hypersensitivity to any other component of the gel. – Patients in whom attacks of asthma, urticaria or acute rhinitis are precipitated by the action of acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs). – Damaged skin, regardless of the type of lesion: exudative dermatitis, eczema, infected lesion, burns or wounds. – Starting from the third trimester of pregnancy (see section 4.6). – Use in children and adolescents under 15 years of age is contraindicated.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor cutaneous use only. Only for adults and adolescents over 15 years of age. Based on the size of the affected area to be treated, apply 2 – 4 g of gel 2 – 4 times a day for a maximum treatment period of two weeks. After application, wash your hands, unless they are the treated area. In the absence of improvement or in case of worsening of the condition after 4 days of treatment, consult your doctor or pharmacist. \u003ci\u003eElderly\u003c\/i\u003e The dosage indicated for adults may be valid. See also paragraph 4.4 \u003ci\u003eChildren and adolescents under 15 years of age \u003c\/i\u003e There are insufficient efficacy and safety data available for children and adolescents under 15 years of age (see also section 4.3). In subjects aged 15 years and older, the patient\/parents of the patient should consult the doctor if treatment with this medicine is necessary for a period of more than 7 days as analgesic therapy or in case of worsening of symptoms. \u003ci\u003ePatients with hepatic or renal insufficiency \u003c\/i\u003e For the use of Flectorartro 1% gel in patients with hepatic or renal insufficiency see section 4.4.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis medicinal product does not require special precautions for storage.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by administering the lowest effective dose for the shortest duration necessary to control symptoms, without exceeding a maximum period of two weeks (See sections 4.2 and 4.8). The possibility of systemic adverse events produced by the application of topical diclofenac cannot be excluded if the preparation is used on large skin areas and for a prolonged period (see product information relating to other systemic forms of diclofenac). Although the onset of effects at a systemic level is very rare, caution should be used when using the gel in patients with renal, cardiac or hepatic impairment, previous history of peptic ulcer or inflammatory bowel disease or haemorrhagic diathesis. Nonsteroidal anti-inflammatory drugs should be used with particular caution in elderly patients, who are more predisposed to the onset of adverse events. Diclofenac for topical use should only be applied to intact, non-broken skin, not to lesions or open wounds. It must not come into contact with the eyes or mucous membranes and must not be ingested. Stop treatment if you develop a skin rash after applying the product. Diclofenac for topical use can be used with non-occlusive dressings, but should not be used with non-breathable occlusive dressings. Patients should be informed about the contraindication to direct sun exposure and artificial UV rays in order to reduce the risk of photosensitivity. The use of gloves is recommended for the physiotherapist. Diclofenac for topical use in gel contains propylene glycol which may cause mild localized skin irritation in some subjects. The presence of methyl benzoate causes irritation of the skin, eyes and mucous membranes.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSince the systemic absorption of diclofenac from topical application of the gel is very low, interactions with other medicinal products are unlikely.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdverse reactions (Table 1) are classified by frequency, the highest frequency first, with the following convention: very common: (\u003e1\/10); common (≥1\/100, \u003c1\/10); uncommon (≥1\/1,000, \u003c1\/100); rare (≥1\/10,000, \u003c1\/1,000); very rare (\u003c1\/10,000); not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eImmune system disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/p\u003e\n\u003cp\u003eNot known: Anaphylactic-type reaction.\u003c\/p\u003e\n\u003cp\u003eInfections and infestations.\u003c\/p\u003e\n\u003cp\u003eVery rare: Pustular eruption.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders.\u003c\/p\u003e\n\u003cp\u003eVery rare: Asthma.\u003c\/p\u003e\n\u003cp\u003ePathologies of the skin and subcutaneous tissue.\u003c\/p\u003e\n\u003cp\u003eCommon: Rash, eczema, erythema, dermatitis (allergic and contact), pruritus.\u003c\/p\u003e\n\u003cp\u003eRare: Bullous dermatitis.\u003c\/p\u003e\n\u003cp\u003eVery rare: Photosensitivity\u003c\/p\u003e\n\u003cp\u003eThe systemic absorption of diclofenac for topical application is very low compared to the levels of the active ingredient present in the plasma after taking oral diclofenac. The probability of systemic side effects (such as gastrointestinal (e.g. bleeding), hepatic or renal disorders) is therefore very low after topical application compared to the frequency of side effects associated with taking oral diclofenac. However, the use of diclofenac on a large skin area may lead to the onset of systemic side effects. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it\/it\/responsabili.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe low systemic absorption of diclofenac for topical use makes the risk of overdose very unlikely. However, side effects similar to those observed after overdose of diclofenac tablets are to be expected in case of accidental ingestion of diclofenac for topical use (1 tube of 100 g contains the equivalent of 1000 mg of diclofenac sodium). In case of accidental ingestion resulting in significant systemic adverse effects, the therapeutic measures normally adopted for the treatment of poisoning by non-steroidal anti-inflammatory drugs should be used. The hypothesis of gastric decontamination and the use of activated charcoal will also be evaluated, especially within a short time after ingestion.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy \u003c\/u\u003e The systemic concentration of diclofenac epolamine is lower after topical administration, compared to oral formulations. In relation to the experience acquired in the context of treatment with NSAIDs for systemic use, the following is recommended: Inhibition of prostaglandin synthesis can negatively affect pregnancy and\/or embryo\/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor in the early stages of pregnancy. The absolute risk of cardiovascular malformations increased from less than 1% to approximately 1.5%. The risk was thought to increase with the dose and duration of therapy. In animals, the administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo-foetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors were administered during the organogenetic period. During the first and second trimester of pregnancy, diclofenac epolamine should not be administered unless strictly necessary. If diclofenac epolamine is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low as possible and the duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: – cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – renal dysfunction, which can progress to renal failure with oligo-hydramnios; the mother and the newborn, close to birth, to: – possible prolongation of bleeding time, and anti-aggregating effect which can occur even at very low doses; – inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated starting from the third trimester of pregnancy. \u003cu\u003eBreastfeeding \u003c\/u\u003e Similar to other NSAIDs, diclofenac is passed into breast milk in small quantities. However, at therapeutic doses of Flectorarthro 1% gel, no effects on the infant are expected. Since no controlled studies have been conducted on breastfeeding women, the product should be used during breastfeeding only under medical supervision. In this case, Flectorarthro 1% gel should not be applied to the breast or to any large area of ​​skin or for a prolonged period of time (see section 4.4).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCutaneous application of topical diclofenac does not alter the ability to drive or use machinery.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":51730211242311,"sku":"041472046","price":13.86,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-flectorartro-1-100-g-gel-in-contenitore-pressurizzato-farmacia-dottor-tili-1213791032.jpg?v=1767164589"},{"product_id":"14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa","title":"Flector Unidie 14 mg 10 piroxicam medicated plasters","description":"\u003cp\u003eFlector Unidie is \u003cstrong\u003epiroxicam 14 mg\u003c\/strong\u003e in a medicated plaster. Piroxicam is a \u003cstrong\u003enon-steroidal anti-inflammatory\u003c\/strong\u003e, and the patch form serves to take it where it is needed without letting it all pass through the stomach: the levels in the blood that are reached this way are much lower than those of the tablet.\u003c\/p\u003e\u003cp\u003eThe name says the most useful thing to know. \u003cstrong\u003eUnidie\u003c\/strong\u003e it means \u003cstrong\u003eone patch every twenty-four hours\u003c\/strong\u003e, only one at a time, and never two on the same day. The cycle must not exceed \u003cstrong\u003eeight days\u003c\/strong\u003e. It applies only to the \u003cstrong\u003eintact skin\u003c\/strong\u003e, after having washed and dried the area well: rub a corner of the patch between your fingers to detach the protective film and place the adhesive part on the skin.\u003c\/p\u003e\u003cp\u003eOn the elbow and knee, which bend a lot, the RCP suggests a \u003cstrong\u003eretention bandage\u003c\/strong\u003e to be placed with the joint flexed, so the patch remains in place even when the joint opens.\u003c\/p\u003e\u003cp\u003eThe things that remain are that, being an NSAID, piroxicam also comes with it through the skin. The blood level is low but \u003cstrong\u003eIt varies a lot from person to person\u003c\/strong\u003e, therefore general effects cannot be excluded, especially on the stomach. And repeated use of skin products can cause \u003cstrong\u003eawareness\u003c\/strong\u003e: if redness, itching or burning appear at the application site, stop. Even better \u003cstrong\u003eavoid direct sun\u003c\/strong\u003e on the treated area, to avoid the risk of photosensitisation. This is the pack from \u003cstrong\u003e10 plasters\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch2\u003eINDICATIONS\u003c\/h2\u003e\n\u003ch3\u003eWhy is Flector Unidie 14 mg 10 piroxicam medicated plasters used? What is it for?\u003c\/h3\u003e\u003cp\u003eFlector Unidie is indicated for the treatment of painful and inflammatory states of a rheumatic and traumatic nature of the joints, muscles, tendons and ligaments.\u003c\/p\u003e\n\u003ch2\u003eACTIVE INGREDIENTS AND EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003eWhat is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eComposition\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eA medicated plaster contains: • active ingredient: piroxicam 14 mg. \u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eExcipients\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAcrylic copolymer, Eudragit E 100; non-woven fabric, silicone polyester.\u003c\/p\u003e\n\u003ch2\u003eDOSAGE\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters taken?\u003c\/h3\u003e\u003cp\u003eDosage It is recommended to use only one medicated plaster at a time and replace it every 24 hours for a period of no more than 8 days. Do not apply two patches on the same day. Flector Unidie is to be used exclusively on intact skin. Method of administration For cutaneous use only. After having carefully washed and dried the painful area, rub one of the corners of Flector Unidie between your fingers to remove the protective film and apply the adhesive part directly to the skin. In the event that Flector Unidie must be applied to joints with greater mobility, such as the elbow or knee, it is advisable to use a retention bandage to be applied to the flexed joint, in order to keep the patch in place. Do not exceed the recommended doses. Avoid contact with eyes and mucous membranes.\u003c\/p\u003e\n\u003ch2\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003eWhen should Flector Unidie 14 mg 10 piroxicam medicated plasters not be used and what side effects can it cause?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eContraindications\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie is contraindicated in the following cases: • hypersensitivity to the active ingredient (piroxicam) or to any of the excipients (see the section \"What is the composition of Flector Unidie 14 mg 10 piroxicam medicated plasters?\"); • patients in whom substances with a similar mechanism of action (NSAIDs) have caused hypersensitivity reactions ((see the section \"What are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\")); • patients with active peptic ulcer; • patients with bronchial asthma; • patients with a history of gastrointestinal bleeding due to NSAIDs; • patients on anticoagulant therapy; • pregnancy and breastfeeding ((see the section \"Can Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\")); • children under 12 years of age. Flector Unidie patch should not be used on open wounds or lesions, but only on intact skin.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSide effects\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe use of the medicine can cause local irritative or allergic skin reactions such as erythema, itching, burning, contact dermatitis, numbness and tingling at the application site; cases of extensive and serious dermatological lesions such as urticaria, Quincke's edema, erythema multiforme have been reported with this type of medicine. Larger and more severe photosensitivity reactions and skin and mucosal reactions, including asthma attacks, are possible. Systemic adverse reactions following the topical use of piroxicam are unlikely; since the plasma levels obtained are lower than those measured after systemic administration but highly variable from individual to individual, it is not possible to exclude, especially in the case of prolonged therapies beyond the recommended term and non-observance of contraindications and warnings, the appearance of systemic side effects, especially at a gastrointestinal level ((see the section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). The possible appearance of general side effects or at the point of application requires suspension of therapy. Cases of fixed drug eruption with unknown frequency (frequency cannot be estimated from the available data) have been reported with piroxicam ((see section \"What are the warnings for Flector Unidie 14 mg 10 piroxicam medicated plasters?\")). Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003eWhich medicines or foods can change the effect of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003eThe use of piroxicam-based patches is unlikely to have interactions with other medicines. However, the possibility of competition between the absorbed piroxicam and other drugs with high binding to plasma proteins cannot be excluded. Do not use the medicine together with other drugs for oral or local use, containing piroxicam or other NSAIDs.\u003c\/p\u003e\n\u003ch2\u003ePREGNANCY AND BREASTFEEDING\u003c\/h2\u003e\n\u003ch3\u003eCan Flector Unidie 14 mg 10 piroxicam medicated plasters be used during pregnancy and breastfeeding?\u003c\/h3\u003e\u003cp\u003ePregnancy and breastfeeding Flector Unidie is contraindicated during pregnancy and breastfeeding and is not recommended in women intending to become pregnant. Fertility Administration should be suspended in women with fertility problems or who are undergoing fertility investigations.\u003c\/p\u003e\n\u003ch2\u003eWARNINGS\u003c\/h2\u003e\n\u003ch3\u003eWhat are the warnings of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003eWarnings and precautions\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThe serum levels achieved with Flector Unidie were significantly lower than those obtained through oral administration but with strong individual variability, therefore the onset of systemic side effects, especially at the gastrointestinal level, cannot be ruled out. Analgesics, antipyretics, non-steroidal anti-inflammatory drugs, including piroxicam, can cause hypersensitivity reactions, potentially serious even in subjects not previously exposed to this type of drugs. These include asthma attacks, skin rashes, allergic rhinitis and anaphylactic-type reactions. Flector Unidie should be used with caution in subjects with chronic obstructive bronchial diseases, allergic rhinitis or inflammation of the nasal mucosa (nasal polyps) in which asthmatic attacks or localized inflammatory reactions of the skin and mucosa (Quincke's edema) are more frequent. Use caution in patients with a history of peptic ulcer, in patients with a history of gastrointestinal bleeding not secondary to the administration of NSAIDs or with other bleeding disorders, in patients with Crohn's disease or ulcerative colitis, with severe hepatic or renal dysfunction or with heart failure. Prolonged or repeated use of products for skin use can give rise to sensitization phenomena. In the presence of hypersensitivity reactions it is necessary to interrupt therapy. Caution should be used when treating elderly patients who are generally more susceptible to adverse events. After a short therapy without results, consult your doctor. To avoid any phenomena of hypersensitivity or photosensitization, avoid exposure to direct sunlight. Skin reactions Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with a history of piroxicam-related FDE. A potential cross-reaction with other oxicams may occur. Pediatric population Keep the medicine out of the sight and reach of children.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eOverdose\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eThere are no known cases of overdose. In case of overdose with evident clinical manifestations, immediately institute symptomatic therapy and apply the common emergency measures of the case.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDriving vehicles and using machinery\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eFlector Unidie does not interfere with the ability to drive vehicles and use machines.\u003c\/p\u003e\n\u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003eHow is Flector Unidie 14 mg 10 piroxicam medicated plasters stored?\u003c\/h3\u003e\u003cp\u003eNo particular storage conditions are necessary.\u003c\/p\u003e\n\u003ch2\u003eFORMAT\u003c\/h2\u003e\n\u003ch3\u003eWhat is the format of Flector Unidie 14 mg 10 piroxicam medicated plasters?\u003c\/h3\u003e\u003cp\u003e\u003cstrong\u003e10 medicated plasters of 14 mg\u003c\/strong\u003e, in paper, polyethylene, aluminum and EAA sachets.\u003c\/p\u003e\n\u003ch2\u003eDRUG LEGAL TEXT\u003c\/h2\u003e\n\u003cp\u003eContent responsibility\u003c\/p\u003e\u003cp\u003eThis sheet contains information that is not intended to replace a doctor's diagnosis or advice, as only the doctor can draw up any prescription and give therapeutic indications. All contents must be understood and are of an exclusively informative nature and aimed exclusively at bringing to the attention of customers or potential customers in the pre-purchase phase of the products sold through this site. In case of pathologies, disorders or allergies it is always best to consult your doctor first.\u003c\/p\u003e\u003cp\u003ePlease note\u003c\/p\u003e\u003cp\u003eThe product names, ingredients and percentages indicated in the descriptions are purely indicative and may be subject to changes or updates by the manufacturing companies. Due to the impossibility of adapting to these updates in real time, the photos and technical information of the products included on Dottortili.com may differ from those shown on the label or otherwise disseminated by the manufacturing companies. The only identification element appears to be the ministerial code MINSAN. The online pharmacy Dottortili.com does not guarantee the truthfulness and timeliness of the information published and declines any responsibility for any errors, omissions or failure to update the same. Dottortili.com assumes no responsibility for damages of any nature that may arise from access to the information published.\u003c\/p\u003e\u003cp\u003eData source: Farmadati Italia\u003c\/p\u003e\u003cp\u003eWebsite: www.farmadati.it\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia database is used by almost all pharmacies, parapharmacies, herbalist shops, health shops, large-scale retail trade, computerized doctors, etc. thanks to the guarantee of historical reliability, seriousness and professionalism of the company on the national territory.\u003c\/p\u003e\u003cp\u003eThe Farmadati Italia S.r.l management system complies with the requirements of the UNI EN ISO 9001:2015 standards for quality management systems and UNI CEI ISO\/IEC 27001:2017 for information security management systems.\u003c\/p\u003e","brand":"Ibsa","offers":[{"title":"Default Title","offer_id":54954303652167,"sku":"038354039","price":25.9,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/ibsa-farmaceutici-italia-srl-14-mg-cerotto-medicato-10-cerotti-in-bustina-carta-pe-al-eaa-farmacia-dottor-tili-1257817163.jpg?v=1789016140"}],"url":"https:\/\/www.dottortili.com\/en\/collections\/flector.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}